368 related articles for article (PubMed ID: 24365380)
1. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
Cambridge G; Perry HC; Nogueira L; Serre G; Parsons HM; De La Torre I; Dickson MC; Leandro MJ; Edwards JC
J Autoimmun; 2014 May; 50():67-76. PubMed ID: 24365380
[TBL] [Abstract][Full Text] [Related]
2. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
de la Torre I; Moura RA; Leandro MJ; Edwards J; Cambridge G
Ann Rheum Dis; 2010 Dec; 69(12):2181-8. PubMed ID: 20581016
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
4. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
[TBL] [Abstract][Full Text] [Related]
6. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
Carter LM; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
[TBL] [Abstract][Full Text] [Related]
8. ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis.
Gremese E; Tolusso B; Fedele AL; Canestri S; Alivernini S; Ferraccioli G
J Rheumatol; 2012 Dec; 39(12):2276-85. PubMed ID: 22984268
[TBL] [Abstract][Full Text] [Related]
9. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
10. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.
de la Torre I; Leandro MJ; Edwards JC; Cambridge G
Clin Exp Rheumatol; 2012; 30(4):554-60. PubMed ID: 22510323
[TBL] [Abstract][Full Text] [Related]
11. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
[TBL] [Abstract][Full Text] [Related]
12. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics.
De La Torre I; Leandro MJ; Valor L; Becerra E; Edwards JC; Cambridge G
Rheumatology (Oxford); 2012 May; 51(5):833-40. PubMed ID: 22253030
[TBL] [Abstract][Full Text] [Related]
13. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
[TBL] [Abstract][Full Text] [Related]
14. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
Becerra E; De La Torre I; Leandro MJ; Cambridge G
Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
[TBL] [Abstract][Full Text] [Related]
15. Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients.
Canestri S; Totaro MC; Serone E; Tolusso B; Frezza D; Gremese E; Ferraccioli G
Reumatismo; 2012 Dec; 64(6):368-73. PubMed ID: 23285480
[TBL] [Abstract][Full Text] [Related]
16. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.
Ferraccioli G; Tolusso B; Bobbio-Pallavicini F; Gremese E; Ravagnani V; Benucci M; Podestà E; Atzeni F; Mannocci A; Biasi D; Manfredi M; Sarzi-Puttini P; Laganà B; Montecucco C
PLoS One; 2012; 7(7):e40362. PubMed ID: 22859946
[TBL] [Abstract][Full Text] [Related]
18. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
20. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
